Psoriasis Symptom Inventory (PSI) as a patient-reported outcome in mild psoriasis: Real life data from a large psoriatic arthritis registry

Correlations between PSI, BSA, and other patient- and physician-reported outcomes were investigated.Results: There was a good correlation between PSI and BSA (r=0.546, p

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objective: Our aim is to test the validity of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome, to assess the psoriasis severity within the scope of rheumatology.Methods: Within the PsA international database (PSART-ID), 571 patients had PSI, while 322 of these also showed body surface area (BSA).

📊

Key Findings & Data:Objective: Our aim is to test the validity of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome, to assess the psoriasis severity within the scope of rheumatology.Methods: Within the PsA international database (PSART-ID), 571 patients had PSI, while 322 of these also showed body surface area (BSA).

💡

Conclusion & Impact:Correlations between PSI, BSA, and other patient- and physician-reported outcomes were investigated.Results: There was a good correlation between PSI and BSA (r=0.546, p

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Objective: Our aim is to test the validity of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome, to assess the psoriasis severity within the scope of rheumatology.Methods: Within the PsA international database (PSART-ID), 571 patients had PSI, while 322 of these also showed body surface area (BSA). Correlations between PSI, BSA, and other patient- and physician-reported outcomes were investigated.Results: There was a good correlation between PSI and BSA (r=0.546, p

🔖

Cite This Article

KILIÇ, L., ÇINAR, M., ERDEN, A., ALHUSSAİN, F. A., ÖZİŞLER, C., ÇETİN, G. Y., SOLMAZ, D., YAVUZ, Ş., TARHAN, E. F., OMMA, A., KİMYON, G., AYDIN, S. Z., GÜNAL, E. K., OSAİMİ, N. A., KÜÇÜK, A., ERSÖZLÜ, E. D., YILDIZ, F., TUF, M. A. (2022). Psoriasis Symptom Inventory (PSI) as a patient-reported outcome in mild psoriasis: Real life data from a large psoriatic arthritis registry. European Journal of Rheumatology, Cilt: 7 - Sayı: 2, 64–67. https://ajindex.com/articles/511566

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (1)

Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010; 69: 48-53. [CrossRef] 2. Bushnell DM, Martin ML, McCarrier K, Gordon K, Chiou CF, Huang X, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-re- ported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat 2013; 24: 356-60. [CrossRef] 3. Martin ML, McCarrier KP, Chiou CF, Gordon K, Kimball AB, Van Voorhees AS, et al. Early devel- opment and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. J Dermatolog Treat 2013; 24: 255-60. [CrossRef] 4. Revicki DA, Jin Y, Wilson HD, Chau D, Viswana- than HN. Reliability and validity of the psoria- sis symptom inventory in patients with mod- erate-to-severe psoriasis. J Dermatolog Treat 2014; 25: 8-14. [CrossRef] 5. Papp K, Menter A, Strober B, Kricorian G, Thompson EH, Milmont CE, et al. Efficacy and safety of broda- lumab in subpopulations of patients with diffi- cult-to-treat moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2015; 72: 436-9. [CrossRef] 6. Feldman SR, Bushnell DM, Klekotka PA, Scanlon M, Martin ML, Wade SW, et al. Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. J Dermatolog Treat 2016; 27: 224-7. [CrossRef] 7. Mease PJ, Genovese MC, Mutebi A, Viswana- than HN, Chau D, Feng J, et al. Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Pso- riatic Arthritis. J Rheumatol 2016; 43: 343-9. [CrossRef ] 8. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64(Suppl 2): 65-8. [CrossRef] 9. Kalyoncu U, Bayindir O, Ferhat Oksuz M, Dogru A, Kimyon G, Tarhan EF, et al. The Psoriatic Ar- thritis Registry of Turkey: results of a multicentre registry on 1081 patients. Rheumatology (Ox- ford) 2017; 56: 279-86. [CrossRef] 10. Aydin SZ, Kilic L, Kucuksahin O, Ureyen SB, Kaly- oncu U. Performances of inflammatory back pain criteria in axial psoriatic arthritis. Rheuma- tology (Oxford) 2017; 56: 2031-2. [CrossRef]